Akari’s TROP2 ADC Uses an RNA Splicing Warhead. Everyone Else Uses Chemo.
Akari Therapeutics showed preclinical data for AKTX-101, a TROP2 ADC with an RNA spliceosome payload.
Jeff Martin
INBRAIN Wrapped Enrollment on the First Human Study of a Graphene Brain Chip
INBRAIN Neuroelectronics completed enrollment in the first-in-human trial of its graphene cortical interface.
Ampersand’s IL-22 Only Wakes Up in the Gut. Nowhere Else.
Ampersand Biomedicines showed preclinical data for AMP-220, a gut-targeted IL-22 therapeutic for IBD.
ViewsML Raises $4.8M Seed With Plans To Replace Tissue Staining With AI.
ViewsML closed a $4.9M seed for AI virtual biomarker staining from standard pathology images.
Kyverna Held the MG Response. For a Full Year.
Kyverna showed 52-week Phase 2 data for miv-cel in generalized myasthenia gravis at AAN.
Verismo’s “NK-Wired” CAR-T Got Its First Clinical Look.
Verismo Therapeutics showed first Phase 1 data for SynKIR-110, a mesothelin KIR-CAR, at AACR plenary.
Debiopharm Got Fast Track for a Double-Inhibitor Combo in Ovarian
Debiopharm got FDA Fast Track for lunresertib + zedoresertib in platinum-resistant ovarian cancer.
Deck Bio Showed DBXO-1 to the Room. The Mechanism Actually Works.
Deck Bio presented preclinical data for DBXO-1, a multi-pMHC TCR-based bispecific TCE, at AACR 2026.
Argo Goes After CFB. Alexion and Apellis Should Look Up.
Argo Biopharma dosed first patients in Phase 2 with an siRNA that silences complement factor B.
AlphaGen Brought Two Pb-212 Programs to AACR. One Already Has Human Imaging Data.
AlphaGen Therapeutics presented preclinical data for Pb-212 radioligands targeting SSTR2 and FAP at AACR 2026.